Login / Signup

Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease.

Qi SunFei YeHao LiangHongbo LiuChunmei LiRoujian LuBaoying HuangLi ZhaoWenjie TanLuhua Lai
Published in: Signal transduction and targeted therapy (2021)
Keyphrases
  • sars cov
  • clinical trial
  • respiratory syndrome coronavirus
  • oxidative stress
  • phase ii
  • open label
  • randomized controlled trial
  • phase iii
  • study protocol